Stealth BioTherapeutics Appoints David A. Brown as Chief Scientific Officer to Advance Mitochondrial Medicine Pipeline
核心洞察
Stealth BioTherapeutics (搜索) has appointed David A. Brown (搜索), Ph.D., as Chief Scientific Officer to lead the company's expanding mitochondrial medicine pipeline.
Brown brings over 25 years of metabolism research experience and has been collaborating with Stealth for nearly 15 years before joining full-time in 2019.
The appointment supports the company's growing pipeline in rare and age-related diseases of mitochondrial dysfunction (搜索), following their first FDA-approved mitochondria (搜索)-targeted therapy.
Stealth BioTherapeutics (搜索), a commercial-stage biotechnology company focused on mitochondrial dysfunction (搜索) therapies, announced the appointment of David A. Brown (搜索), Ph.D., as Chief Scientific Officer effective immediately. The appointment signals the company's expansion of its executive team to support a growing proprietary pipeline targeting rare and age-related diseases involving mitochondrial dysfunction.
Leadership Transition Builds on Long-Standing Collaboration
Brown brings more than 25 years of metabolism research experience to his new role, having previously collaborated with Stealth for nearly 15 years as a scientific collaborator and consultant before joining the company full-time in 2019. His scientific expertise spans basic mitochondrial biology through bioenergetic dysfunction in various pathologies, with extensive experience designing and testing novel approaches to target cellular energy production.
"Stealth has greatly benefited from David's expertise in mitochondrial biology and cellular energetics for nearly 15 years – first in his role as one of our scientific collaborators and then through his in-house portfolio and team leadership," said Reenie McCarthy (搜索), Chief Executive Officer of Stealth BioTherapeutics (搜索). "We are thrilled to appoint David as our Chief Scientific Officer as we advance our growing pipeline in rare and age-related diseases of mitochondrial dysfunction (搜索)."
Academic Background and Industry Experience
Prior to his full-time role at Stealth, Brown served as a tenured professor and held numerous academic leadership roles. He led a mitochondrial research laboratory that collaborated with biotechnology companies focused on treating neurodegenerative, metabolic, genetic, ophthalmic, and cardiac pathologies (搜索). At Stealth, he most recently served as Senior Vice President of Discovery, overseeing the company's drug discovery team and portfolio expansion efforts.
Brown has authored hundreds of scientific publications, served as an expert reviewer for funding agencies and scientific journals, and founded two consulting companies. He earned a Bachelor of Science from Virginia Tech, a Ph.D. from the University of Colorado, and completed post-doctoral training at the Johns Hopkins University School of Medicine.
Pipeline Advancement Following FDA Approval
The appointment comes as Stealth builds on its recent milestone of delivering what the company describes as the first-ever mitochondria (搜索)-targeted therapy to patients. The company's first commercial product received accelerated approval from the U.S. Food & Drug Administration in September 2025.
"I am energized by the work we do at Stealth every day to translate deep knowledge of mitochondrial bioenergetics into new medicines for people facing debilitating diseases," said Brown. "I am deeply honored to become the Company's Chief Scientific Officer and build on our recent milestone of delivering the first-ever mitochondria (搜索)-targeted therapy to patients in need."
Current Development Portfolio
Stealth is currently studying elamipretide in additional indications, including dry age-related macular degeneration (搜索) and primary mitochondrial disease (搜索) due to nuclear DNA mutations, including in polymerase gamma (搜索). The company is also developing its next-in-class clinical-stage candidate, bevemipretide, for ophthalmic and neurological disease indications.
The company's preclinical pipeline includes candidates SBT-589 and SBT-255 (搜索), both of which are progressing through developmental milestones. McCarthy emphasized that the executive team expansion "paves the way for continued innovation in a range of mitochondrial diseases and solidifies our position as the pioneer in mitochondrial medicine."